资源类型：
WOS体系：
Pubmed体系：
收录情况：
◇ SCIE
文章类型：
单位：
[1]Department of Urology,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,China.
外科学系
华中科技大学同济医学院附属同济医院
泌尿外科
ISSN：
关键词：
Novel androgen receptor inhibitors
Androgen deprivation therapy
Metastatic hormone-sensitive prostate cancer
Treatment choice
摘要：
Androgen receptor (AR) signaling is essential in prostate cancer treatment. For many years, androgen deprivation therapy (ADT) has been primarily applied to manage advanced prostate cancer. However, most individuals with metastatic hormone-sensitive prostate cancer (mHSPC) administered ADT alone are at risk of developing metastatic castration-resistant prostate cancer (mCRPC) in less than two years. New approaches employing novel AR inhibitors (ARi) as intensified upfront systemic treatment in mHSPC have recently demonstrated substantial benefits in delaying disease progression and prolonging overall survival. Administration of novel ARi has become the new standard of care in mHSPC. The new landscape simultaneously makes treatment choice more challenging. This review provides comprehensive data on molecular structure, pharmaceutical properties, and efficacy and safety profiles reported by pivotal clinical trials. We also discuss future directions with ongoing Phase III trials of novel ARi in mHSPC. Considering these biological and clinical insights, this review aimed to provide a comprehensive understanding of differences in the development and applications of novel ARi for mHSPC, which may be helpful in designing strategies for first-line treatment choices.Copyright © 2023 The Authors. Published by Elsevier Masson SAS.. All rights reserved.
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2022]版：
大类
|
2 区
医学
小类
|
1 区
药学
2 区
医学：研究与实验
最新[2025]版：
大类
|
2 区
医学
小类
|
2 区
医学：研究与实验
2 区
药学
JCR分区：
出版当年[2021]版：
Q1
MEDICINE, RESEARCH & EXPERIMENTAL
Q1
PHARMACOLOGY & PHARMACY
最新[2023]版：
Q1
MEDICINE, RESEARCH & EXPERIMENTAL
Q1
PHARMACOLOGY & PHARMACY
影响因子：
最新[2023版]
最新五年平均
出版当年[2021版]
出版当年五年平均
出版前一年[2020版]
出版后一年[2022版]
第一作者：
第一作者单位：
[1]Department of Urology,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,China.
共同第一作者：
通讯作者：
推荐引用方式(GB/T 7714)：
Xia Qi-Dong,Zhang Si-Han,Zeng Na,et al.Novel androgen receptor inhibitors for metastatic hormone-sensitive prostate cancer: Current application and future perspectives[J].BIOMEDICINE & PHARMACOTHERAPY.2023,168:doi:10.1016/j.biopha.2023.115806.
APA：
Xia Qi-Dong,Zhang Si-Han,Zeng Na,Lu Yu-Chao,Qin Bao-Long&Wang Shao-Gang.(2023).Novel androgen receptor inhibitors for metastatic hormone-sensitive prostate cancer: Current application and future perspectives.BIOMEDICINE & PHARMACOTHERAPY,168,
MLA：
Xia Qi-Dong,et al."Novel androgen receptor inhibitors for metastatic hormone-sensitive prostate cancer: Current application and future perspectives".BIOMEDICINE & PHARMACOTHERAPY 168.(2023)
